Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2018-01-17T17:03:31-05:00
Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study2018-01-17T17:03:31-05:00
Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis2018-01-17T17:01:59-05:00
Therapeutic Considerations for Disease Progression in Multiple Sclerosis Therapeutic Considerations for Disease Progression in Multiple Sclerosis2018-01-17T17:01:30-05:00
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis2018-01-17T17:01:19-05:00
Toward the Development of Rational Therapies in Multiple Sclerosis: What Is on the Horizon? Toward the Development of Rational Therapies in Multiple Sclerosis: What Is on the Horizon?2018-01-17T17:00:25-05:00
